GLP-1 and Smoking Cessation: What Semaglutide Could Mean for Quitting

Real-world data from 222,000 patients, active Phase 2 trials, and the dopamine-reward mechanism that explains why GLP-1 users report losing the desire to smoke.

Among the most unexpected findings from GLP-1 research: people on semaglutide are reporting that they simply stop wanting cigarettes. This isn't just anecdotal — a major study in the Annals of Internal Medicine used real-world data from over 222,000 patients to quantify the effect, and multiple clinical trials are now actively testing semaglutide as a smoking cessation tool.

The Annals of Internal Medicine Study: 222,942 Patients

Published in August 2024, this target trial emulation used electronic health records from 64 major U.S. healthcare organizations covering 113 million patients. Researchers compared 5,967 new semaglutide users with tobacco use disorder against users of seven other diabetes medications. Ann Intern Med 2024

Semaglutide showed a significantly lower risk for tobacco-related medical encounters across all seven comparisons, including against other GLP-1 receptor agonists (HR 0.88), suggesting this may be a semaglutide-specific effect rather than a class effect. The reduction in smoking cessation medication prescriptions and counseling visits was also significant, suggesting people were quitting without needing traditional cessation aids.

Critically, these effects appeared within 30 days of starting semaglutide — too fast to be explained by weight loss alone, pointing toward a direct neurological mechanism.

The Mechanism: Dopamine and the Reward System

GLP-1 receptors are expressed in the brain's mesolimbic dopamine pathway — the same reward circuitry that drives nicotine addiction. Preclinical research from 2017 identified that GLP-1 acts on the medial habenula, a brain region that mediates avoidance of nicotine's aversive effects. Activating GLP-1 receptors in this circuit appears to reduce the rewarding properties of nicotine. Nature Neurosci 2017

This is the same dopamine-reward pathway mechanism that explains GLP-1 medications' observed effects on alcohol consumption, cannabis use, and even compulsive gambling — all of which have been documented in observational studies. The common thread is that GLP-1 agonists appear to modulate the intensity of reward signals for addictive substances.

Active Clinical Trials

Several trials are currently underway to test these observations in randomized controlled settings:

The failed dulaglutide trial is worth noting: researchers believe dulaglutide's failure may be due to its larger molecular size limiting blood-brain barrier penetration and thus reducing central nervous system effects compared to semaglutide. This would be consistent with semaglutide showing stronger effects in the real-world data.

The Weight Gain Connection

Fear of weight gain is one of the most commonly cited reasons smokers relapse. Post-cessation weight gain averages 4–5 kg in the first year, with some individuals gaining significantly more. If semaglutide can simultaneously reduce cravings and prevent weight gain, it would address both barriers to quitting at once — which is exactly what the ongoing trials are designed to test.

Where Things Stand: Can You Use GLP-1s for Smoking Cessation Today?

No GLP-1 medication is FDA-approved for smoking cessation, and the current evidence — while compelling — comes from observational studies that cannot establish causation. Randomized trial results are needed before clinical practice changes can be justified. The researchers behind the Annals study were explicit about this limitation.

That said, if you are already on a GLP-1 for weight management or diabetes and you happen to smoke, the data suggests you may experience reduced cravings as a secondary benefit. This is worth discussing with your provider.